Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Sort by Product ID

Click to order products descending

Display 45 Products per page

Gralise
Read More
Gralise (gabapentin; Depomed) is an extended-release formulation of gabapentin, an analog of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), and is used for treatment of restless leg syndrome and post-herpetic neuralgia (PHN).
May 31, 2018
Find out more
Donaperminogene Seltoplasmid
Read More
Donaperminogene seltoplasmid (ViroMed), also referred to as VM202, is a DNA-based drug that is designed to produce two isoforms of HGF (hepatocyte growth factor), HGF728 and HGF723. When VM202 is delivered to the affected area by a single intramuscular injection, the drug enters a small portion of the surrounding muscle cells.
May 31, 2018
Find out more
Cebranopadol
Read More
Cebranopadol is a novel small molecule analgesic, which was discovered by Grünenthal. Cebranopadol represents a novel, first-in-class potent analgesic that has a dual mechanism of action as a potent agonist of both the nociceptin/orphanin FQ peptide receptor (NOP) and opioid peptide receptor.
May 31, 2018
Find out more
IMO-2125
Read More
IMO-2125 is a synthetic phosphorothioate oligonucleotide-based agonist of toll-like receptor 9 (TLR9) designed to mimic the bacterial DNA that normally activates TLR9.
May 23, 2018
Find out more
Seviprotimut-L
Read More
Seviprotimut-L (Polynoma/CK Life Sciences) is a polyvalent, shed-antigen vaccine in development for the adjuvant treatment of Stage IIb–III melanoma patients. Seviprotimut-L contains a combination of antigens from three proprietary melanoma cell lines, and is intended to stimulate the body’s immune system to fight cancer.
May 23, 2018
Find out more
PDR001
Read More
PDR001 (Novartis) is a fully humanized monoclonal antibody designed to inhibit the negative immunoregulatory receptor programmed death-1 (PD-1). PDR001 blocks the interaction between PD-1 and its ligands, programmed death-ligand 1 (PD-L1) and PD-L2; the signaling elicited by this interaction inhibits T-cell activation.
May 23, 2018
Find out more
Daromun
Read More
Daromun (Philogen) is a combination of Darleukin, a human vascular targeting monoclonal antibody (L19) fused to interleukin-2 (IL-2), and Fibromun, the L19 antibody linked to tumor necrosis factor (TNF). Both IL-2 and TNF are cytokines, key signaling molecules that are involved with the coordination of immunity.
May 23, 2018
Find out more
Rebinyn
Read More
Rebinyn is a glycoPEGylated rebombinant factor IX (rfIX) therapy developed by Novo Nordisk for the treatment of hemophilia B.
May 20, 2018
Find out more
Hemlibra
Read More
Hemlibra is an anti-factor IXa/X bispecific antibody, developed by Roche as a new treatment option for hemophilia A patients.
May 20, 2018
Find out more
Valoctocogene Roxaparvovec
Read More
Valoctocogene roxaparvovec (BioMarin), also known as valrox, is an adeno-associated virus-mediated gene therapy that delivers human B domain-deleted coagulation factor VIII (fVIII) to patients with hemophilia A.
May 20, 2018
Find out more
SPK-9001
Read More
SPK-9001 is Spark Therapeutics’ leading candidate in development for hemophilia B.
May 4, 2018
Find out more
SPK-8011
Read More
Spark Therapeutics’ SPK-8011 is an adeno-associated virus-mediated gene therapy, aiming to restore normal clotting function to patients with hemophilia A.
May 4, 2018
Find out more
Fitusiran
Read More
Alnylam, in conjunction with its development partner Sanofi, is developing fitusiran for the treatment of hemophilia A and B.
May 4, 2018
Find out more
AMT-061
Read More
AMT-061 is being developed by uniQure as a gene therapy for hemophilia B patients. The product uses an adeno-associated virus as a vector to deliver the highly active Padua factor IX (fIX) variant, which has eightfold to ninefold greater activity than normal, wild-type fIX.
May 4, 2018
Find out more
Afstyla
Read More
Afstyla is a single-chain recombinant factor VIII (rfVIII) product developed by CSL Behring to have a longer duration of action than standard rfVIII. Endogenously produced fVIII consists of a light chain and a heavy chain fused via a metal ion bridge.
May 4, 2018
Find out more
Nuwiq
Read More
Nuwiq (Octapharma) is a B-domain deleted recombinant factor VIII (rfVIII) therapy developed for the treatment of adult and pediatric patients with hemophilia A.
May 4, 2018
Find out more
Vonvendi
Read More
Vonvendi (Shire) became the first recombinant von Willebrand factor (rVWF) therapy approved in the US in December 2015.
May 4, 2018
Find out more
Lu AF35700
Read More
Lu AF35700 (Lundbeck) has a novel pharmacological profile as a dopamine D1 and D2 antagonist with a high occupancy of 5-HT2A and 5-HT6 serotonin receptors.
March 19, 2018
Find out more
Nuplazid
Read More
Nuplazid (Acadia Pharmaceuticals) contains pimavanserin, which is a selective serotonin inverse agonist preferentially targeting the serotonin 5-HT2A receptors.
March 19, 2018
Find out more
MIN-101
Read More
MIN-101 (Minerva Neurosciences/Mitsubishi Tanabe) is a novel antagonist of the sigma-2 and serotonin 5-HT2A receptors.
March 19, 2018
Find out more
Lonasen
Read More
Lonasen (Sumitomo Dainippon/Nitto Denko) contains blonanserin, a dopamine D2 and serotonin 5-HT2 receptor antagonist.
March 19, 2018
Find out more
Trelegy Ellipta
Read More
Trelegy Ellipta ([fluticasone furoate + vilanterol + umeclidinium bromide]; GlaxoSmithKline) is a fixed triple combination inhaled corticosteroid/long-acting beta 2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) therapy.
July 31, 2018
Find out more
Fasenra
Read More
Fasenra (benralizumab; AstraZeneca/Kyowa Hakko Kirin) is a humanized monoclonal antibody which binds to the alpha chain of the interleukin (IL)-5 receptor on eosinophils and therefore depletes them.
February 16, 2018
Find out more
Dupixent
Read More
Dupixent (dupilumab; Regeneron/Sanofi) is an injectable monoclonal antibody directed against the interleukin (IL)-4 receptor alpha subunit, which blocks signaling from both IL-4 and IL-13.
February 16, 2018
Find out more
Bevyxxa
Read More
Bevyxxa (betrixaban; Portola Pharmaceuticals) is approved in the US for the prophylaxis of VTE in adult patients hospitalized for an acute medical illness.
January 23, 2018
Find out more
Zoladex
Read More
Zoladex (goserelin; AstraZeneca/TerSera Therapeutics) is a gonadotropin-releasing hormone (GnRH) receptor agonist which acts on the pituitary gland to stimulate luteinizing hormone (LH) release, resulting in a temporary surge in serum testosterone levels known as “flare.”
January 18, 2018
Find out more
Trelstar
Read More
Trelstar (triptorelin; Allergan) is a gonadotropin-releasing hormone (GnRH) receptor agonist which acts on the pituitary gland to stimulate luteinizing hormone (LH) release, resulting in a temporary surge in serum testosterone levels known as “flare.”
January 18, 2018
Find out more
Firmagon
Read More
Firmagon (degarelix; Ferring/Astellas) is a gonadotropin-releasing hormone (GnRH) receptor antagonist that directly binds to GnRH receptors in the anterior pituitary gland, rapidly reducing the circulating gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and leading to the rapid suppression of testosterone in men.
January 18, 2018
Find out more
Eligard
Read More
Eligard (leuprolide; Astellas/Tolmar Pharmaceuticals) is a gonadotropin-releasing hormone (GnRH) receptor agonist which acts on the pituitary gland to stimulate luteinizing hormone (LH) release, resulting in a temporary surge in serum testosterone levels known as “flare.”
January 18, 2018
Find out more
Yonsa
Read More
Yonsa (Churchill Pharmaceuticals) is an oral, ultramicrosize tablet formulation of abiraterone acetate that inhibits 17 alpha-hydroxylase (CYP17). The CYP17 family of enzymes catalyze the hydroxylation of intermediates involved in testosterone synthesis, a common driver of prostate cancer genesis and recurrence.
January 18, 2018
Find out more
Relugolix
Read More
Relugolix (Myovant Sciences/Takeda) is a gonadotropin-releasing hormone (GnRH) receptor antagonist that directly inhibits GnRH receptors, rapidly reducing the circulating gonadotropin’s luteinizing hormone (LH) and follicle-stimulating hormone (FSH) and leading to the suppression of testosterone in men.
January 18, 2018
Find out more
Ipatasertib
Read More
Ipatasertib (Roche) is a highly selective, ATP-competitive Akt inhibitor that preferentially targets active, phosphorylated Akt.
February 26, 2020
Find out more
Apalutamide
Read More
Apalutamide (Johnson & Johnson) is an orally available androgen signaling inhibitor. The drug exhibits high binding affinity to the ligand-binding domain of androgen receptor (AR) and subsequently inhibits its nuclear import, as well as its ability to bind to DNA. Apalutamide has a similar mechanism of action to Xtandi (enzalutamide; Pfizer/Astellas).
January 18, 2018
Find out more
Darolutamide
Read More
Darolutamide is a non-steroidal oral androgen receptor (AR)antagonist in development by Bayer for the treatment of prostate cancer. Darolutamide potently inhibits the binding of androgens to ARs, blocking nuclear translocation of ARs and AR-mediated gene expression. The AR signaling pathway is the primary pathway that drives prostate cancer growth.
January 18, 2018
Find out more
Dexferrum
Read More
Dexferrum (iron dextran; Luitpold Pharmaceuticals) is an intravenous (IV) iron maintenance treatment used to help elevate hemoglobin levels in patients with anemia in chronic kidney disease (CKD).
January 11, 2018
Find out more
Feraheme
Read More
Feraheme (ferumoxytol; AMAG Pharmaceuticals) is an intravenous (IV) iron maintenance treatment used to help elevate hemoglobin levels in patients with anemia in chronic kidney disease (CKD).
January 11, 2018
Find out more
Injectafer
Read More
Injectafer (ferric carboxymaltose; Vifor/Luitpold Pharmaceuticals/Zeria) is an iron maintenance treatment used to help elevate hemoglobin levels in patients with anemia in chronic kidney disease (CKD). It is administered intravenously and is dissociated into iron and sucrose once in circulation.
January 11, 2018
Find out more
NeoRecormon
Read More
NeoRecormon (epoetin beta; Roche/Chugai) is an erythropoiesis-stimulating agent (ESA) administered by intravenous (IV) or subcutaneous (SC) injection, and is indicated for the treatment of anemia in chronic kidney disease (CKD).
January 11, 2018
Find out more
Dengvaxia
Read More
Dengvaxia (tetravalent live-attenuated chimeric vaccine; Sanofi Pasteur) is a tetravalent vaccine comprised of four monovalent, chimeric live-attenuated vaccines (LAVs).
January 4, 2018
Find out more
Omecamtiv Mecarbil
Read More
Omecamtiv mecarbil is a novel cardiac myosin activator that increases contractility in heart muscle through selectively activating the enzyme myosin ATPase.
December 11, 2017
Find out more
Vericiguat
Read More
Vericiguat is a first-in-class soluble guanylate cyclase (sGC) stimulator that acts to increase levels of cyclic guanosine monophosphate (cGMP) via the nitric oxide-sGC-cGMP pathway.
December 11, 2017
Find out more
Ofatumumab
Read More
Ofatumumab (Genmab/Novartis) is a fully human immunoglobulin G1 and high-affinity antibody that targets a novel epitope on cluster of differentiation (CD)20 on the B-cell membrane. Ofatumumab binds effectively to both the small and large extracellular loops on CD20 and releases very slowly over time.
November 24, 2017
Find out more
ALKS 8700
Read More
ALKS 8700 is an oral monomethyl fumarate molecule being developed for the treatment of relapsing multiple sclerosis.
November 24, 2017
Find out more
Ocrevus
Read More
Ocrevus is a second-generation cluster of differentiation (CD)20 antibody. Similar to Roche’s blockbuster cancer drug Rituxan (rituximab), Ocrevus specifically targets CD20+ B cells, thus depleting lymphocytes that produce the autoimmune response.
November 24, 2017
Find out more
Mavenclad
Read More
Mavenclad contains cladribine, a small molecule that suppresses the immune system by selectively targeting lymphocytes, which are cells that seem to be major players in MS pathological mechanisms.
November 24, 2017
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *